Viral Vectors and Plasmid DNA Manufacturing Market Report 2026

The viral vectors and plasmid dna manufacturing market size has grown exponentially in recent years. It will grow from $7.11 billion in 2025 to $8.79 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to growth in gene therapy research programs, expansion of vaccine development initiatives, increasing academic and clinical research funding, early commercialization of cell therapies, advancements in molecular biology techniques.

The viral vectors and plasmid dna manufacturing market size is expected to see exponential growth in the next few years. It will grow to $20.36 billion in 2030 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to increasing approvals of gene and cell therapies, rising demand for commercial-scale manufacturing, expansion of CMO partnerships, growing focus on rare disease treatments, continued innovation in vector design and production efficiency. Major trends in the forecast period include increasing deployment of scalable viral vector manufacturing platforms, rising adoption of single-use bioprocessing systems, growing demand for high-purity plasmid dna, expansion of contract manufacturing capacity, enhanced focus on regulatory-compliant production.

The growing number of gene therapies is expected to drive the expansion of the viral vectors and plasmid DNA manufacturing market in the coming years. Gene therapy involves the introduction, removal, or modification of genetic material within a patient’s cells to prevent or treat disease. Its advancement is fueled by increasing investment in biotechnology research and a deeper understanding of the genetic and cellular mechanisms underlying various disorders. Viral vectors and plasmid DNA manufacturing are critical for delivering therapeutic genes into patient cells, enabling treatment of genetic conditions at the molecular level. For example, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials rose by 10% in Q3 2023, marking the first quarterly increase since Q3 2022. As a result, the rise in gene therapy development is driving growth in the viral vectors and plasmid DNA manufacturing market.

Companies in the viral vectors and plasmid DNA manufacturing market are increasingly pursuing strategic partnerships to expand production capacity, enhance technological capabilities, and accelerate the global development and commercialization of gene therapies. Such collaborations allow companies to share resources and infrastructure, boosting overall manufacturing capacity to meet the rising demand for gene therapy products. For instance, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, partnered with Captain T Cell, a spin-off from the Max Delbrück Center in Berlin, Germany, to launch a plasmid DNA and retroviral vector production program. The collaboration provides Captain T Cell with access to established contract development and manufacturing (CDMO) services and advisory support, aiming to expedite the progression from preclinical research to clinical trials for a novel TCR-T cell therapy targeting solid tumors.

In December 2023, Polyplus, a France-based biochemistry laboratory, acquired Xpress Biologics for an undisclosed sum. This acquisition expands Polyplus’ product portfolio and enhances its plasmid DNA manufacturing capabilities, which are essential for gene and cell therapies. The move is expected to strengthen Polyplus’ position in the rapidly growing gene therapy sector. Xpress Biologics, a Belgium-based contract development and manufacturing organization (CDMO), specializes in producing plasmid DNA and proteins through microbial expression systems.

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH.

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vectors and plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vectors and plasmid DNA manufacturing market by increasing costs of imported bioreactors, filtration systems, reagents, and quality control equipment essential for GMP-compliant production. Manufacturers in North America and Europe are most affected due to reliance on specialized imported bioprocessing tools, while Asia-Pacific faces cost pressures in scaling export-oriented manufacturing. These tariffs are raising capital expenditure and production costs. However, they are also encouraging domestic biomanufacturing investments, regional supply chain localization, and expansion of in-house production capabilities.

The viral vectors and plasmid dna manufacturing market research report is one of a series of new reports that provides viral vectors and plasmid dna manufacturing market statistics, including viral vectors and plasmid dna manufacturing industry global market size, regional shares, competitors with a viral vectors and plasmid dna manufacturing market share, detailed viral vectors and plasmid dna manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors and plasmid dna manufacturing industry. This viral vectors and plasmid dna manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vectors and plasmid DNA manufacturing refers to the production processes used to create viral vectors and plasmid DNA, which are critical components in gene therapy, vaccine development, and genetic research. These manufacturing processes involve sophisticated biotechnological techniques to ensure the safety, effectiveness, and consistency of the final products.

The primary product types in the viral vectors and plasmid DNA manufacturing market include plasmid deoxyribonucleic acid (DNA), viral vectors, and non-viral vectors. Plasmid DNA consists of small, circular DNA molecules commonly utilized in genetic research and biotechnology applications. These products are manufactured at various operational scales, including preclinical, clinical, and commercial levels. The market supports multiple therapeutic areas, such as oncology, rare diseases, neurology, sensory disorders, metabolic disorders, musculoskeletal disorders, hematological disorders, immunological disorders, and others, for applications in gene therapies, cell therapies, and vaccines. Production is carried out by both in-house manufacturers and contract manufacturing organizations (CMOs).

The viral vectors and plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as process development, cell line development, and analytical and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vectors and plasmid DNA manufacturing market also includes sales of bioreactors, cell culture systems, reagents and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.